AtaGenix Laboratories
AtaGenix Laboratories
AtaGenix provides large-scale antibody and protein production from milligram pilot runs to multi-gram manufacturing batches — using CHO-K1, XtenCHO™, and HEK293 mammalian platforms with bioreactor capacity up to 200 L.
200 L
Bioreactor Capacity
2–4 wks
Transient Turnaround
>95%
Purity (SDS-PAGE)
10 g+
Max Delivery Scale
Case Highlight — Mouse IgG2a produced via transient CHO at 200 L scale: 288 mg/L yield, 1.97 g total delivery, SDS-PAGE >95%, SEC-HPLC >99% monomer, 4-week turnaround from DNA to shipped product.
| Format | Species / Variants |
| Full-length IgG | Mouse, rabbit, human, camelid — all subclasses |
| Antibody fragments | Fab, scFv, VHH / nanobody |
| Bispecific formats | CrossMAb, BiTE, IgG-scFv, DVD-Ig |
| Fc-fusion & scaffolds | Receptor-Fc, enzyme-Fc, therapeutic scaffolds |
Transient or Stable — Your Call
Need material next month? Transient CHO/HEK gets you there. Need consistent supply for 12+ months? We build a clonal cell line with documented stability and regulatory-ready process records. Same QC pipeline either way.
One Vendor, Every Format
IgG, nanobody, bispecific, Fc-fusion — we handle format-specific vector design, expression optimization, and purification in-house. No subcontracting, no finger-pointing when timelines slip.
Ship-Ready, Worldwide
Every batch ships with lot-specific CoA, cold-chain packaging, and export documentation. Add SPR/BLI kinetics, FACS, neutralization assays, lyophilization, or custom aliquoting as needed.
AtaGenix's scale-up platform bridges discovery and manufacturing. Transient CHO/HEK293 expression delivers up to 200 L batches in 2–4 weeks for rapid in vivo material supply. For projects requiring lot-to-lot consistency and regulatory documentation, stable cell pool or clonal cell line production provides gram-scale output with defined process parameters. Both routes share the same downstream pipeline: Protein A/G or Ni-NTA affinity capture, SEC polishing, endotoxin removal, and a comprehensive QC package (SDS-PAGE, SEC-HPLC, BCA, LAL, CoA).
A standardized 4-stage pipeline from gene sequence to gram-scale purified antibody with QC at every checkpoint.
01
Gene & Vector
Codon optimization
Vector design
Plasmid amplification
02
Pilot Expression
Small-scale transfection
Titer verification
Quality pre-check
03
Scale-Up Production
Up to 200 L transient
or stable pool fermentation
Fed-batch optimization
04
Purification & QC
Protein A/G + SEC
Endotoxin removal
SDS-PAGE, SEC-HPLC, CoA
Service Scope
| ✓ Transient CHO / HEK293 (up to 200 L) | ✓ Stable cell pool or clonal cell line production |
| ✓ Full-length IgG, Fab, scFv, VHH, bispecifics | ✓ Fc-fusion proteins and therapeutic scaffolds |
| ✓ Protein A/G + SEC polishing purification | ✓ Endotoxin removal (<0.1 EU/mg) |
| ✓ Full QC: SDS-PAGE, SEC-HPLC, BCA, endotoxin | ✓ Optional: SPR/BLI binding, FACS, neutralization |
| ✓ Buffer exchange, lyophilization, custom aliquoting | ✓ Cold-chain global shipping with export documentation |
Two routes, same QC standards. Pick based on timeline and lot consistency requirements.
| Factor | Transient (CHO/HEK) | Stable Pool / Cell Line |
|---|---|---|
| Timeline | 2–4 weeks | 8–16 weeks |
| Typical Scale | 10 mg – 2 g | 1 g – 10 g+ |
| Lot Consistency | Batch-to-batch variation | High consistency (clonal) |
| Regulatory Path | Research / preclinical | IND-enabling, CMC-ready |
| Best For | In vivo studies, lead characterization | Kit production, clinical supply, CMO transfer |
Starting smaller? Explore our CHO Transient or HEK293 Transient for milligram-scale feasibility, then scale up when your lead is confirmed. Or go directly to a CHO Stable Cell Line for long-term manufacturing-ready supply.
What is the maximum production scale AtaGenix can support?
Our current bioreactor capacity supports transient expression up to 200 L per batch. For projects requiring larger volumes, we run multiple batches in parallel or transition to stable cell pool production for consistent multi-gram supply. Typical single-batch yields range from 10 mg to 2 g (transient) or 1–10 g+ (stable pool/cell line).
When should I choose transient vs. stable pool production?
Choose transient when speed is the priority — 2–4 weeks from DNA to purified antibody, ideal for in vivo studies and lead characterization. Choose stable pool or clonal cell line when you need lot-to-lot consistency, regulatory documentation, or repeated production campaigns over months to years.
What antibody formats can be produced at scale?
We support full-length IgG (all subclasses, mouse/rabbit/human/camelid), Fab, scFv, VHH/nanobody, bispecific formats (CrossMAb, BiTE, IgG-scFv), and Fc-fusion proteins. Each format follows an optimized expression and purification workflow tailored to its specific requirements.
What QC data is provided with each batch?
Every batch ships with a lot-specific Certificate of Analysis (CoA) including SDS-PAGE (reducing + non-reducing), SEC-HPLC (monomer/aggregate profile), endotoxin (LAL assay, <0.1 EU/mg standard), and protein concentration (BCA or A280). Optional add-ons include SPR/BLI binding kinetics, FACS, neutralization assays, and stability studies.
Timelines and yields depend on antibody format, expression system, and production scale. Quote-based pricing. GMP-grade scope available upon request.
Contact Us
+86-27-6552-3339
info@atagenix.com
Building C, R & D Building, No. 666, Shendun 4th Road, Donghu New Technology Development Zone, Wuhan
